<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Generally <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> can be simply and curatively treated </plain></SENT>
<SENT sid="1" pm="."><plain>However, large and long-standing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> can be locally very destructive and in rare cases even <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasize</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Hedgehog pathway inhibitors such as vismodegib constitute a new and promising therapy for metastatic or locally advanced <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>CASE DESCRIPTION: We describe a patient with metastasized <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> and <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome who, in the context of a study, was successfully treated with vismodegib </plain></SENT>
<SENT sid="4" pm="."><plain>The main undesirable effects in our patient were <z:hpo ids='HP_0003394'>muscle cramps</z:hpo>, loss of taste, <z:hpo ids='HP_0002018'>nausea</z:hpo> and <z:hpo ids='HP_0001596'>hair loss</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0002671'>Basal cell carcinoma</z:hpo> is potentially a locally destructive <z:e sem="disease" ids="C0037286" disease_type="Neoplastic Process" abbrv="">skin tumour</z:e> that only very rarely <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasizes</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Hedgehog pathway inhibitors such as vismodegib can be administered in a selected group of patients with <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> </plain></SENT>
</text></document>